Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

It's been a mediocre week for AnaptysBio, Inc. (NASDAQ:ANAB) shareholders, with the stock dropping 11% to US$19.68 in the week since its latest quarterly results. Revenues of US$28m beat estimates by a substantial 82% margin. AnaptysBio also reported a statutory loss of US$1.28 per share, which was roughly in line with what the analysts predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've discovered 3 warning signs about AnaptysBio. View them for free.

Taking into account the latest results, the eleven analysts covering AnaptysBio provided consensus estimates of US$60.3m revenue in 2025, which would reflect a substantial 46% decline over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$5.40. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$48.5m and losses of US$5.19 per share in 2025. Ergo, there's been a clear change in sentiment, with the analysts lifting this year's revenue estimates, while at the same time increasing their loss per share numbers to reflect the cost of achieving this growth.

See our latest analysis for AnaptysBio

There was no major change to the consensus price target of US$37.82, with growing revenues seemingly enough to offset the concern of growing losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on AnaptysBio, with the most bullish analyst valuing it at US$57.00 and the most bearish at US$18.00 per share. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the AnaptysBio's past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 56% by the end of 2025. This indicates a significant reduction from annual growth of 1.9% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that AnaptysBio's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for AnaptysBio going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 3 warning signs for AnaptysBio (1 doesn't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.